Core Viewpoint - Jinxin Fertility (01951.HK) reported a significant decline in mid-term performance for the period ending June 30, 2025, with a revenue drop of 10.75% year-on-year and a shift from profit to loss for shareholders [1] Financial Performance - The company's mid-term revenue was 1.289 billion RMB, reflecting a year-on-year decrease of 10.75% [1] - Shareholder losses amounted to 1.04 billion RMB, compared to a profit of 190 million RMB in the same period last year [1] - Basic loss per share was reported at 0.39 RMB [1] Operational Challenges - The decline in revenue was attributed to several factors, including a decrease in OPU cycles, an increase in IUI cycle patients, adjustments in national medical insurance leading to lower average prices per cycle, and a 24% drop in traditional delivery volumes affecting obstetric income [1] - In Chengdu, the number of egg retrieval cycles decreased by 6.1% year-on-year, primarily due to a reduction in first-time patients and a significant increase in the proportion of IUI cycles [1] Service Expansion - Since the launch of the third-generation IVF services in 2024, the company has served over 1,500 patients [1]
锦欣生殖中期股东应占亏损10.4亿元